13. Fratiglioni L., De Ronchi D., Aguero-Torres H. Worldwide prevalence and incidence of dementia // Drugs Aging.– 1999.– V.15.– P.365-375.
14. Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer’ disease // J Neural Transm.– 2002.– V.62 (Suppl).– P.181-187.
15. Ritchie C.W., Ames D., Clayton T., Lai R. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease // Am J Geriatr Psychiatry.– 2004.– V.12.– P.358-369.
16. McShane R. et al. Memantine for dementia. Cochrane Database of Systematic Reviews.– Oxford: Update Software, 2006.
17. Tariot P.N. et al. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil // JAMA.– 2004.– V.291, No.3.– P.317–324.
18. Mazza M., Capuano A., Bria P.,Mazza, S. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer's dementia in a randomized placebo-controlled double-blind study // European Journal of Neurology.– 2006.– V.13.– P.981–985.
19. Wang B.-S., Wang H., Song Y.-Y. et al. Effectiveness of Standardized Ginkgo biloba Extract on Cognitive Symptoms of Dementia with a Six-Month Treatment: A Bivariate Random Effect Meta-Analysis // Pharmacopsychiatry.– 2010.– V.43, No.3.– P.86-91.
20. Zandi P.P., Carlson M.C., Plassman B.L. et al. Hormone replacement therapy and incidence of Alzheimer's disease on older women: the Cache County study // JAMA.– 2002.– V.288.– P.2123-2129.
21. Santen R.J., Allred D.C., Ardoin S.P., Archer D.F., Boyd N., Braunstein G.D. et al. Endocrine Society. Postmenopausal hormone therapy: an Endocrine Society Scientific Statement // J Clin Endocrinol Metab.– 2010.– V.95.– S.1–66.
22. Thal L.J., Grundman M., Berg J. et al. Idebenone treatment fails to slow cognitive decline in Alzheimer's disease // Neurology.– 2003.– V.61, No.11.– P.1498–1502.
23. Trinh N.H., Hoblyn J., Mohanty S. et al. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis // JAMA.– 2003.– V.289.– P.210-216.
24. Winblad B., Fioravanti M., Dolezal T., Logina I., Milanov I.G., Popescu D.C., Solomon Therapeutic use of nicergoline // Clin Drug Investig.– 2008.– V.28, No.9.– P.533-552.
25. Rottkamp C.A., Nunomura A., Hirai K. et al. Will antioxidants fulfill their expectations for the treatment of Alzheimer disease? // Mech Ageing Dev.– 2000.– V.116.– P.169-179.
26. Zandi P.P., Anthony J.C., Khachaturian A.S. et al. Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County Study // Arch Neurol.– 2004.– V.61.– P.82-88.
27. Scarmeas N., Stern Y., Tang M.X. et al. Mediterranean diet and risk for Alzheimer’s disease // Ann Neurol.– 2006.– V.59.– P.912-921.
28. Li G., Larson E.B., Sonnen J.A. et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease // Neurology.– 2007.– V.69.– P.878-885.
29. Cataldo J.K., Glantz K., Stanton A. Smoking cessation and Alzheimer's disease: Facts, fallacies and promise // Expert Review of Neurotherapeutics.– 2010.– V.10, No.5.– P.629-631.
30. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? // Nat Med.– 2006.– V.12.– P.1005-1015.
31. Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimer’s disease anti-inflammatory Prevention Trial (ADAPT) // PLoS. Clin Trials.– 2006.– V.1.– E33.
32. Tuszynski M.H. Nerve growth factor gene therapy in Alzheimer disease. Alzheimer // Dis Assoc Disord.– 2007.– V.21.– P.179-189.
33. Tuszynski M.H., Thal L., Pay M. et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease // Nat Med.– 2005.– V.11.– P.551-555.
Более подробно http://medicinecare.blogspot.com/p/blog-page_21.html